Date: August 14, 2026
Regulatory Disclosure
Neuland Laboratories Limited has disclosed that the United States Food and Drug Administration (US FDA) conducted an inspection of its Unit 3 manufacturing facility. The facility is located at Gaddapotharam village, Jinnaram, Sangareddy District. The inspection period was from August 10, 2026, to August 14, 2026.
At the conclusion of the inspection, the US FDA issued a Form 483 containing one observation. The observation specifically pertains to procedural improvements required in water and environmental monitoring systems. The improvement involves expanding monitoring protocols to include new organisms beyond those currently listed in the United States Pharmacopeia (USP).
The company has stated that it will submit its formal response to the US FDA's observation within the stipulated timelines.
Other Sections
Financial Results: Not Specified
Dividend Declaration: Not Specified
KMP / Board / Auditor Changes: Not Specified
Board Meeting Outcomes: Not Specified
Auditor’s Report: Not Specified
Disinvestment / Strategic Actions: Not Specified
Media Release / Investor Communication: Not Specified